Table 2.
All-cause mortality among NSCLC Patients diagnosed between 1987 and 2012, the ACTUR and SEER registries
| Variables | Numbers | Adjusted HR* | 95% CI | |
|---|---|---|---|---|
| Alive | Dead | |||
| Overall | ||||
| SEER | 7700 | 57328 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 1895 | 14362 | 0.78 | 0.76 to 0.81 |
| By Age | ||||
| <50 | ||||
| SEER | 877 | 3931 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 272 | 930 | 0.66 | 0.60 to 0.74 |
| 50–64 | ||||
| SEER | 3534 | 24482 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 916 | 6088 | 0.78 | 0.75 to 0.81 |
| 65–80 | ||||
| SEER | 2921 | 25595 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 645 | 6484 | 0.81 | 0.78 to 0.85 |
| >80 | ||||
| SEER | 368 | 3320 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 62 | 860 | 0.74 | 0.66 to 0.82 |
| By Sex | ||||
| Male | ||||
| SEER | 4110 | 39406 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 958 | 9921 | 0.79 | 0.76 to 0.82 |
| Female | ||||
| SEER | 3590 | 17922 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 937 | 4441 | 0.77 | 0.73 to 0.81 |
| By Race | ||||
| White | ||||
| SEER | 6050 | 48722 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 1433 | 12260 | 0.80 | 0.77 to 0.82 |
| Black | ||||
| SEER | 775 | 5957 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 238 | 1445 | 0.67 | 0.62 to 0.73 |
| Asian or Pacific Islander | ||||
| SEER | 767 | 2505 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 199 | 619 | 0.84 | 0.74 to 0.96 |
| By Stage & | ||||
| Stage I | ||||
| SEER | 4372 | 12389 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 1197 | 3550 | 0.87 | 0.80 to 0.95 |
| Stage II | ||||
| SEER | 538 | 2846 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 147 | 912 | 1.00 | 0.72 to 1.37 |
| Stage III | ||||
| SEER | 1290 | 14435 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 239 | 3781 | 0.76 | 0.70 to 0.83 |
| Stage IV | ||||
| SEER | 930 | 20785 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 147 | 4510 | 0.72 | 0.67 to 0.76 |
| Unknown | ||||
| SEER | 570 | 6873 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 165 | 1609 | 0.86 | 0.75 to 0.98 |
| By Grade | ||||
| Well Differentiated | ||||
| SEER | 981 | 2529 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 379 | 841 | 0.73 | 0.50 to 1.06 |
| Moderately Differentiated | ||||
| SEER | 2287 | 10588 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 537 | 3004 | 0.76 | 0.69 to 0.85 |
| Poorly Differentiated | ||||
| SEER | 2237 | 21914 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 462 | 5344 | 0.81 | 0.76 to 0.86 |
| Undifferentiated | ||||
| SEER | 213 | 3789 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 35 | 491 | 0.81 | 0.55 to 1.21 |
| Unknown | ||||
| SEER | 1982 | 18508 | 1.00 (Ref.) | 1.00 (Ref.) |
| ACTUR | 482 | 4682 | 0.73 | 0.68 to 0.78 |
*
All HRs were adjusted for tumor stage, tumor grade and region at diagnosis. In stratified analysis, tumor stage was not adjusted in the analysis stratified by tumor stage, and tumor grade was not adjusted in the analysis stratified by tumor grade.
&
For stages I and II patients, HRs were adjusted for tumor grade, region at diagnosis and surgery. For stages III and IV patients, HRs were adjusted for tumor stage, region at diagnosis and radiation.
HR, Hazard Ratio
CI, Confidence Interval